About
OncoC4 is a privately held, late-stage biopharmaceutical company engaged in the discovery and development of novel biologicals for treating cancer and immunological diseases. Its pipeline features assets with first-in-class and best-in-class potential. AI-081 is a potentially best-in-class bispecific antibody candidate currently enrolling patients in a Phase 1/2 trial. OncoC4 also has a collaboration with BioNTech to co-develop gotistobart.
Rockville